title: [Adjuvant treatment for resected colon cancer].
abstract: Adjuvant treatment has clearly demonstrated its efficacy and safety in resected colon cancer patients, saving thousands of lives every year worldwide. Six months adjuvant chemotherapy combining 5FU and oxaliplatin (FOLFOX or XELOX regimens) is indicated in stage III colon cancer after surgical removal of the primary tumor. The benefit of adjuvant chemotherapy seems less evident in stage II colon cancer, but this treatment should be discussed in patients with "high risk" factors for recurrence. Patient's age is also an important factor for adjuvant treatment decision. The challenge in the future will be to establish predictive and prognostic scores able to offer an even more personalized adjuvant therapeutic approach.
authors: Anne-Laure
authors: AL
authors: Pointet
authors: Céline
authors: C
authors: Lepère
authors: Julien
authors: J
authors: Taieb
mesh_terms: D000465:Algorithms; D017024:Chemotherapy, Adjuvant; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control